

For Public Release

NZX Limited
Wellington

11 April 2024

Cannasouth Announces CEO Resignation

Cannasouth Limited (NZX:CBD) announces the resignation of CEO, Mark Lucas, effective 8 April 2024.

When Cannasouth announced the appointment of voluntary administrators on 28 March 2024, Mr Lucas offered the administrators his full support as and when required throughout the course of the administration.

The Administrators would like to thank Mr Lucas for his co-operation through this process to date.

-ENDS-

For further information visit www.cannasouth.co.nz or contact:

Garry Whimp

Administrator, Blacklock Rose Ltd
Email: gwhimp@blr.co.nz
Mobile: 021 587 230

Ben Francis

Administrator, Blacklock Rose Ltd
Email: bfrancis@blr.co.nz
Mobile: 021 042 6991

About Cannasouth Limited

Cannasouth is a vertically integrated biopharmaceutical Group. The Group has been established to focus on the commercial development of the medicinally beneficial attributes of cannabinoid compounds produced by the cannabis plant, and other health products and medicines. Our goal is to support patients' health outcomes and improve their quality of life. Our products are produced under GMP, using environmentally friendly methods, ensuring patients are treated with therapeutic products of the highest quality. Cannasouth Limited is the parent company, listed on the NZX, and is 100% owner of Cannasouth Bioscience Ltd, Cannasouth Cultivation Ltd and Eqalis Group New Zealand Ltd.

For video footage, photos and logos please visit: <https://www.cannasouth.co.nz/about/media/>